Find a company by name or ticker and open its page
We use analytics cookies to understand how you use Stockoscope and improve the platform. Essential cookies that keep you logged in are always on. Cookie policy
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
BSX24/7 Wall StreetPre-Market Stock Futures: Futures are trading lower this Friday, with the Nasdaq down almost 2.
Also in the news
Zacks Investment Research
Zacks Investment Research
247 Wallst
BSXZacks Investment ResearchBoston Scientific faces a challenging 2027 as cybersecurity disruptions, EP and WATCHMAN weakness and China pricing pressures weigh on growth prospects.
BSXBenzingaBoston Scientific Corp (NYSE:BSX) on Wednesday posted upbeat third-quarter financial results and cut its FY26 guidance below estimates.
BSXPRNewsWireALAMEDA, Calif., Oct. 29, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2026.
BSXMarketBeatBoston Scientific NYSE: BSX reported third-quarter 2026 results that fell below its prior guidance after a cybersecurity incident disrupted manufacturing and product shipments for eight business days, while competitive and pricing pressures weighed on key cardiovascular franchises.
BSXSeeking AlphaBoston Scientific Corporation (BSX) Q3 2026 Earnings Call Transcript
BSXZacks Investment ResearchBoston Scientific's third-quarter revenues beat estimates, but contracting margins, weaker segment sales and reduced 2026 guidance weigh on shares.
BSXZacks Investment ResearchThe headline numbers for Boston Scientific (BSX) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
BSXZacks Investment ResearchBoston Scientific (BSX) came out with quarterly earnings of $0.73 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.75 per share a year ago.
BSXWSJBoston Scientific lowered its outlook, as it expects to end a difficult year with a fourth-quarter sales decline.